Two articles made the headlines this week that focused on biomarkers of kidney disease. The first was the announcement of a $1M grant awarded to an Australian firm for the discovery and development of biomarkers for diabetic kidney disease. The second was a new paper from French researchers which was published in the Journal of the American Society of Nephrology. They found increased levels of autoantibodies in patients suffering from IgA Nephropathy. Both articles cite the need for better biomarkers for early detection of kidney damage, a subject that the Predictive Safety Testing Consortium has also addressed. Myriad RBM has been a part of that effort and our KidneyMAP products are aimed at offering scientists and clinicians better markers of kidney damage.